| Drug Class | Examples | Monitoring |
| Direct Oral Anticoagulants (DOACs) | Apixaban, Rivaroxaban, Dabigatran, Edoxaban | Renal function; no routine INR |
| Vitamin K Antagonist | Warfarin | INR target 2.0–3.0 |
| Low Molecular Weight Heparin | Enoxaparin, Dalteparin | Anti-Xa (renal impairment, extremes weight) |
| Unfractionated Heparin | IV infusion | aPTT or anti-Xa |
DOACs preferred for most (no monitoring, fewer interactions, similar efficacy/safety). Duration: 3 months (provoked), 6–12 months or indefinite (unprovoked, recurrent, cancer).
Adjunctive Measures
- Compression stockings: 20–30 mmHg, knee-high; reduce post-thrombotic syndrome (PTS) risk. Start early if tolerated.
- Elevation: Leg above heart when sitting/lying.
- Early ambulation: Not contraindicated; improves symptoms.
- Analgesia: NSAIDs (caution with anticoagulants), acetaminophen; avoid aspirin unless indicated.
Interventional / Surgical
- IVC filter: Only if anticoagulation contraindicated (active bleed, recent surgery) + acute proximal DVT/PE. Retrievable preferred; remove when safe.
- Catheter-directed thrombolysis (CDT) / pharmacomechanical thrombectomy: Selected iliofemoral DVT <14 days, low bleed risk, good functional status — to prevent PTS.
- Venous stenting: For chronic obstructive lesions (May-Thurner).
- Surgical thrombectomy: Rare; phlegmasia cerulea dolens, failed CDT.
Follow-Up
- Assess bleeding risk (HAS-BLED), renal function, adherence.
- Evaluate for PTS (Villalta scale) at 3–6 months.
- Cancer screening if unprovoked DVT >40 (per guidelines).
Blood Disorders - Related Articles